[1] Mott FW. Chondrosarcoma springing from the sella turcica[J]. Arch Neurol Psychiat,1899, 1:432-433. [2] Coltrera MD, Googe PB, Harrist TJ, et al. Chondrosarcoma of the temporal bone:diagnosis and treatment of 13 cases and review of the literature[J]. Cancer,1986, 58(12):2689-2696. [3] Seidman MD, Nichols RD, Raju UB, et al. Extracranial skull base chondrosarcoma[J]. Ear Nose Throat J, 1989, 68(8):626-632. [4] Jo VY, Doyle LA. Refinements in sarcoma classification in the current 2013 world health organization classification of tumours of soft tissue and bone[J]. Surg Oncol Clin N Am, 2016, 25(4):621-643. [5] Korten AG, ter Berg HJ, Spincemaille GH, et al. Intracranial chondrosarcoma:review of the literature and report of 15 cases[J]. J Neurol Neurosurg Psychiatry, 1998, 65(1):88-92. [6] Chi J, Zhang M, Kang J. Classical intracranial chondrosarcoma:a case report[J]. Oncol Lett,2016, 12(5):4051-4053. [7] 梁娟,钱璐,薛凤麟,等. 颅内间叶性软骨肉瘤2例临床病理分析[J]. 临床与实验病理学杂志,2016,32(10):1171-1173. [8] 牛晓辉. 2017版NCCN《骨肿瘤临床实践指南》更新与解读[J]. 中华外科杂志, 2017, 55(1):41-43. [9] Bloch OG, Jian BJ, Yang I, et al. A systematic review of intracranial chondrosarcoma and survival[J]. J Clin Neurosci, 2009, 16(12):1547-1551. [10] Weber DC, Malyapa R, Albertini F, et al. Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy[J]. Radiother Oncol, 2016, 120(1):169-174. [11] Feuvret L, Bracci S, Calugaru V, et al. Efficacy and safety of adjuvant proton therapy combined with surgery for chondrosarcoma of the skull base:a retrospective, population-based study[J]. Int J Radiat Oncol Biol Phys, 2016,95(1):312-321. [12] Uhl M, Mattke M, Welzel T, et al. High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy:first report of long-term results[J]. Cancer, 2014, 120(10):1579-1585. [13] Morii T, Ohtsuka K, Ohnishi H, et al. BH3 mimetics inhibit growth of chondrosarcoma-a novel targeted-therapy for candidate models[J]. Anticancer Res, 2014, 34(11):6423-6430. [14] Sun X, Charbonneau C, Wei L, et al. CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis[J]. Mol Cancer Ther,2013, 12(7):1163-1170. |